Skip to main content

Table 1 Selected trials of non-oncology drugs in healthy volunteers.

From: Reviewing the role of healthy volunteer studies in drug development

NCT number Treatment Target/MOA Study design Outcomes Enrolled (N)
Completed clinical trials
 NCT01396161 PF-05175157 Acetyl-CoA carboxylase inhibitor Randomized, double-blind, placebo-controlled PK, safety 64
 NCT00741026 Olanzapine Muscarinic (M3) receptor antagonist Randomized, double-blind, placebo-controlled PK, safety 15
 NCT00894322 Exenatide GLP-1 receptor agonist Randomized, single-blind PK, safety 65
 NCT01380730 Evolocumab PCSK9 monoclonal antibody inhibition Randomized, quadruple-blind, placebo-controlled PK, safety 629
 NCT00924053 Bexagliflozin SGLT-2 inhibitor Randomized, quadruple-blind, placebo-controlled PK, safety 24
  1. GLP-1, glucagon-like peptide 1; MOA, mechanism of action; PCSK9, proprotein convertase subtilisin/kexin type 9; PK, pharmacokinetics; SGLT-2, sodium–glucose cotransporter-2